What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Internal medicine, Sarcoma, Surgery, Chemotherapy and Oncology are his primary areas of study.
His study ties his expertise on Osteosarcoma together with the subject of Internal medicine.
His studies in Sarcoma integrate themes in fields like Cancer, Prospective cohort study and Survival analysis.
His research in Surgery intersects with topics in Gastroenterology and Primary tumor.
His Chemotherapy research incorporates elements of Survival rate and Methotrexate.
His Oncology study incorporates themes from Malignancy, Retrospective cohort study, Study groups, Large study and Histological response.
His most cited work include:
- Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. (916 citations)
- Osteosarcoma treatment - where do we stand? A state of the art review. (630 citations)
- Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. (552 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Sarcoma, Surgery, Oncology and Osteosarcoma.
His Gastroenterology research extends to the thematically linked field of Internal medicine.
His Sarcoma study combines topics in areas such as Survival rate and Cancer.
His Surgery research includes themes of Primary tumor, Metastasis and Toxicity.
In his study, Metastasectomy is inextricably linked to Lung, which falls within the broad field of Osteosarcoma.
His Chemotherapy research is multidisciplinary, incorporating elements of Necrosis and Methotrexate.
He most often published in these fields:
- Internal medicine (39.92%)
- Sarcoma (41.18%)
- Surgery (32.77%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (39.92%)
- Oncology (30.25%)
- Sarcoma (41.18%)
In recent papers he was focusing on the following fields of study:
Paul A. Meyers focuses on Internal medicine, Oncology, Sarcoma, Osteosarcoma and Cancer research.
His work deals with themes such as Cancer, Clinical trial and Etoposide, Chemotherapy, Doxorubicin, which intersect with Oncology.
His research on Chemotherapy concerns the broader Surgery.
His Sarcoma research entails a greater understanding of Pathology.
His research in Osteosarcoma tackles topics such as Histological response which are related to areas like Study groups, Large study and Multivariate analysis.
The various areas that Paul A. Meyers examines in his Cancer research study include Neuroendocrine tumors, Cell culture, Phase i study and Mutation.
Between 2014 and 2021, his most popular works were:
- Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial (205 citations)
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial (174 citations)
- EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment (157 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Osteosarcoma, Oncology, Chemotherapy and Ifosfamide.
He studied Osteosarcoma and Young adult that intersect with Interquartile range, Confidence interval, Biopsy and Cohort.
His biological study deals with issues like Clinical trial, which deal with fields such as Precision medicine and Immunohistochemistry.
His study with Chemotherapy involves better knowledge in Surgery.
His Surgery research integrates issues from Neoadjuvant therapy, Primary tumor and Urology.
His studies deal with areas such as Pediatrics, Sarcoma, Recursive partitioning and Doxorubicin as well as Etoposide.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
